TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31972009
Drug: TNFR1 (>3441
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR1 (>3441 pg/mL) in children age 10 years or younger
Study: 31972009
Drug: REG3α (>25
Approvals — FDA: no, EMA: no, PMDA: no
Description: REG3α (>25 ng/mL) in children age 10 years or younger
Study: 31972009
Drug: ST2 (>26
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST2 (>26 ng/mL) in patients older than age 10 years
Study: 31972009
Drug: TNFR1 (>3441
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR1 (>3441 pg/mL) in patients older than age 10 years
Study: 31972009
Drug: REG3α (>25
Approvals — FDA: no, EMA: no, PMDA: no
Description: REG3α (>25 ng/mL) in patients older than age 10 years
Study: 31977002
Drug: Avadomide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (3 to 5 mg) administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal.
Study: 31977002
Drug: Avadomide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (3 to 5 mg) administered on intermittent 5/7-day schedule.
Study: 31978210
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months.
Study: 31978210
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg administered by IV infusion.
Study: 31978221
Drug: Crovalimab (680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab (680 mg; 4 mL), administered subcutaneously once every 4 weeks
Study: 31978886
Drug: ROTEM-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM-based therapy
Study: 31980466
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician/patient decision
Study: 31982162
Drug: Early BM-MNC
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Early BM-MNC treatment (5-7 days after AMI)
Study: 31982162
Drug: Late BM-MNC
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Late BM-MNC treatment (3-4 weeks after AMI)
Study: 31982610
Drug: Endoscopic eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic eradication therapy (EET) leading to complete eradication of intestinal metaplasia (CE-IM)
Study: 31984235
Drug: LDL-c less
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-c less than 70 mg/dL
Study: 31984235
Drug: LDL-c of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-c of 100 ± 10 mg/dL
Study: 31984451
Drug: Nevanimibe HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Nevanimibe (DB16254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevanimibe HCl at doses ranging from 1.6 mg/kg/day to 158.5 mg/kg/day
Study: 31985467
Drug: Donepezil 10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day
Study: 31986140
Drug: Nifurtimox eflornithine
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox eflornithine combination therapy (NECT)
Study: 31986169
Drug: Periodontal scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal scaling and root planing (SRP) treatment
Study: 31987969
Drug: Conformal photon
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal photon radiation therapy (RT)
Study: 31988230
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate prescribing (PIP) at admission and discharge, assessed using the newest screening tool for older persons' potentially inappropriate prescriptions.
Study: 31988230
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug reactions (ADRs) during hospitalisation.
Study: 31988230
Drug: Polypharmacy, defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy, defined as the number of chronic prescribed medications.
Study: 31988972
Drug: Delafloxacin 300
Normalized name: delafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 300 mg twice daily
Study: 31989725
Drug: Intrathecal Baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Baclofen (ITB) therapy
Study: 31989856
Drug: Paclitaxel-Eluting Stent
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-Eluting Stent (Eluvia Drug-Eluting Stent)
Study: 31992396
Drug: Hypoglossal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglossal nerve stimulation (HNS) therapy
Study: 31992396
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with OSA (conservative therapy or observation)
Study: 31992606
Drug: Step-based care
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-based care model comprising psychotherapy, medication management, family support/education, peer support, and vocational/educational support.
Study: 31993192
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 2)
Study: 31993192
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 1)
Study: 31993192
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (both pools)
Study: 31993275
Drug: Herbal gel
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal gel (Hiora SG)
Study: 31995012
Drug: Benidipine +
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine + β-blocker (n=1,089)
Study: 31995012
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three regimens (benidipine + ARB, β-blocker, thiazide)
Study: 31996201
Drug: Trans-oral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-oral endoscopic thyroid surgery
Study: 31998285
Drug: Neonatal antibiotic
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal antibiotic treatment
Study: 31998643
Drug: High-dose ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose ipilimumab (IPI) 10 mg/kg IV every 3 weeks for four doses starting at week 1 and high-dose interleukin-2 (IL-2) 600,000 IU/kg IV bolus every 8 h for up to 14 doses concurrently with IPI at weeks 4 and 7.
Study: 31998643
Drug: Maintenance IPI
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance IPI (10 mg/kg IV) monotherapy administered every 12 weeks for up to 1 year after the first 12 weeks of combination therapy.
Study: 31998643
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with high-dose IPI and high-dose IL-2.